Prenatal Dx Test Firm Verinata Raising $48.5M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fetal chromosomal abnormality test developer Verinata Health today announced it has raised about $46.5 million toward a Series C financing round that is expected to bring in a total of $48.5 million.

The San Carlos, Calif.-based company added that it expects to raise the remaining $2 million and close the round on Aug. 31.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.